ANL 28.35 Decreased By ▼ -1.65 (-5.5%)
ASC 15.14 Decreased By ▼ -0.56 (-3.57%)
ASL 23.65 Decreased By ▼ -0.55 (-2.27%)
AVN 95.60 Decreased By ▼ -3.20 (-3.24%)
BOP 9.20 Increased By ▲ 0.10 (1.1%)
BYCO 10.07 Decreased By ▼ -0.38 (-3.64%)
DGKC 132.50 No Change ▼ 0.00 (0%)
EPCL 48.70 Decreased By ▼ -0.21 (-0.43%)
FCCL 24.55 Decreased By ▼ -0.50 (-2%)
FFBL 25.63 Decreased By ▼ -0.33 (-1.27%)
FFL 16.00 Decreased By ▼ -0.65 (-3.9%)
HASCOL 11.06 Decreased By ▼ -0.13 (-1.16%)
HUBC 84.20 Decreased By ▼ -0.79 (-0.93%)
HUMNL 7.27 Decreased By ▼ -0.33 (-4.34%)
JSCL 24.65 Decreased By ▼ -1.75 (-6.63%)
KAPCO 36.10 Decreased By ▼ -1.00 (-2.7%)
KEL 4.05 Decreased By ▼ -0.07 (-1.7%)
LOTCHEM 14.76 Decreased By ▼ -0.58 (-3.78%)
MLCF 46.00 Decreased By ▼ -0.73 (-1.56%)
PAEL 38.75 Decreased By ▼ -0.90 (-2.27%)
PIBTL 12.05 Decreased By ▼ -0.40 (-3.21%)
POWER 10.60 Decreased By ▼ -0.35 (-3.2%)
PPL 90.60 Decreased By ▼ -1.00 (-1.09%)
PRL 26.30 Decreased By ▼ -0.85 (-3.13%)
PTC 9.14 Increased By ▲ 0.04 (0.44%)
SILK 1.40 Decreased By ▼ -0.04 (-2.78%)
SNGP 39.00 Decreased By ▼ -0.80 (-2.01%)
TRG 138.75 Increased By ▲ 1.15 (0.84%)
UNITY 32.15 Decreased By ▼ -0.85 (-2.58%)
WTL 1.56 Decreased By ▼ -0.08 (-4.88%)
BR100 4,874 Decreased By ▼ -45.25 (-0.92%)
BR30 25,236 Decreased By ▼ -341.52 (-1.34%)
KSE100 45,363 Decreased By ▼ -366.17 (-0.8%)
KSE30 18,884 Decreased By ▼ -101.17 (-0.53%)
Pakistan

Pakistan evaluating China’s clinical trials proposal, informs Mirza

“Too early to say anything!” added Mirza indicating that the decision might take some time. China’s pharmaceut
24 Apr 2020
  • “Too early to say anything!” added Mirza indicating that the decision might take some time.
  • China’s pharmaceutical company Sinopharm, claimed to have developed a vaccine for the coronavirus and has invited Pakistan’s National Institute of Health for clinical trials.

Pakistan is currently evaluating a Chinese pharmaceutical company offer to conduct clinical trials of inactivated novel coronavirus (COVID-19) vaccines in the country, informed Special Assistant for Health, Zafar Mirza on Friday.

“About vaccine for COVID-19: Pakistan is approached by a Chinese company for possible trails. We have asked for more information, which we will evaluate through relevant experts from safety, ethics, regulation and feasibility perspectives before deciding,” said Zafar Mirza, at his Twitter handle.

“Too early to say anything!” added Mirza indicating that the decision might take some time. The statement comes after China’s pharmaceutical company Sinopharm, claimed to have developed vaccine for the coronavirus and has invited Pakistan’s National Institute of Health for clinical trials.

“Through our representative HealthBee Projects Private Limited, we would like to extend our offer for cooperation on conducting clinical trials of our recently developed inactivated COVID-19 vaccine to the National Institute of Health (NIH) in our brotherly country, Pakistan,” read the letter sent to Major General Prof Dr. Aamir Ikram, Executive Director of National Institute of Health, by the general manager of China Sinopharm International Corp., Li Can.

“We hope that a successful clinical trial in Pakistan will make it one of the first few countries for the launch of a COVID-19 vaccine. The is the mission that Sinopharm has been given by the government," read the letter.

Talking to local media, Dr. Ikram informed that the public would get the good news within three months if it all goes well, and was hopeful that they would cover all the testing processes in three months period.